COMT Polymorphism and Entacapone Efficacy

Summary

Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity determined by a genetic polymorphism. The aim of this study is to investigate whether the genetic variability influences entacapone efficacy in Parkinson's disease.

Timeline

Start

2006-10

Primary completion

2009-11

Completion

2009-11

Drugs

Indications